{"id":"dilazep","rwe":[],"tags":[{"label":"dilazep","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Equilibrative nucleoside transporter 1","category":"target"},{"label":"SLC29A1","category":"gene"},{"label":"SCN1A","category":"gene"},{"label":"SCN2A","category":"gene"},{"label":"C01DX10","category":"atc"},{"label":"Active","category":"status"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["dilazep","dilazep dihydrochloride","dilazep hydrochloride","dilazep HCl"],"offLabel":[],"synonyms":["dilazep","dilazep dihydrochloride","dilazep hydrochloride","dilazep HCl"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"target":"Equilibrative nucleoside transporter 1, Sodium channel alpha subunits; brain (Types I, II, III), Equilibrative nucleoside transporter 2","targets":[{"gene":"SLC29A1","source":"DrugCentral","target":"Equilibrative nucleoside transporter 1","protein":"Equilibrative nucleoside transporter 1"},{"gene":"SCN1A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 1 subunit alpha"},{"gene":"SCN2A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 2 subunit alpha"},{"gene":"SCN3A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 3 subunit alpha"}],"modality":"Small Molecule","drugClass":"dilazep","explanation":"Think of the ENT1 transporter like a gate that controls what enters a cell. When DILAZEP blocks this gate, it can affect the levels of certain molecules inside the cell. This can have various effects on the body, depending on the specific molecules involved and the cells affected.","oneSentence":"DILAZEP works by blocking the ENT1 transporter, which regulates the flow of certain molecules into cells.","technicalDetail":"DILAZEP acts as a competitive inhibitor of the ENT1 transporter, which is a transmembrane protein responsible for the facilitated diffusion of nucleosides and nucleoside analogs across cell membranes."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/893","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DILAZEP","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:43:10.527521","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T11:16:58.853867+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"nesiritide","drugSlug":"nesiritide","fdaApproval":"2001-08-10","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"vericiguat","drugSlug":"vericiguat","fdaApproval":"2021-01-19","patentExpiry":"Nov 26, 2032","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"dilazep","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"nesiritide","brandName":"nesiritide","genericName":"nesiritide","approvalYear":"2001","relationship":"same-class"},{"drugId":"vericiguat","brandName":"vericiguat","genericName":"vericiguat","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"F8KLC2BD5Z","CHEBI":"CHEBI:92842","INN_ID":"2779","UMLSCUI":"C0012367","ChEMBL_ID":"CHEMBL126075","KEGG_DRUG":"D07843","DRUGBANK_ID":"DB13715","PDB_CHEM_ID":"8DZ","PUBCHEM_CID":"3074","IUPHAR_LIGAND_ID":"4717","SECONDARY_CAS_RN":"20153-98-4","MESH_DESCRIPTOR_UI":"D004109"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":384,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"C01DX10","allCodes":["C01DX10"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"DILAZEP","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DILAZEP is a small molecule. Its exact mechanism and indications are not specified in the provided facts.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T11:16:58.853867+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}